Advertisement
Advertisement
U.S. markets open in 40 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Green Hygienics Holdings Inc. (GRYN)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.3700+0.0800 (+6.20%)
At close: 3:58PM EDT
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    Green Hygienics Holdings Inc. (GRYN) Announces US$100 Million Green Bond Offering

    SAN DIEGO, Sept. 22, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Green Hygienics Holdings Inc. (OTCQB: GRYN) (“Green Hygienics” or the “Company”) is pleased to announce the offering of a green bond exclusively in Europe (the “Offering”) in the principal amount of US$100 million. The offering is issued for a five-year term with a yield of 7.25%, is not convertible, does not include warrants and is expected to close on or about Nov 30, 2021, subject to the satisfaction of certain customary closin

  • GlobeNewswire

    Green Hygienics Holdings Inc. (GRYN) to Become First Hemp Company to Develop ESG Report Using SASB Framework

    SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Green Hygienics Holdings Inc. (OTCQB: GRYN) (“Green Hygienics” or the “Company”), is pleased to be the first industrial hemp company in the U.S. to announce the publication of its annual Environmental, Social and Governance Report (“ESG Report”) using the Sustainability Accounting Standards Board (SASB) framework. This inaugural report demonstrates the Company's goal to set the benchmark in the industry and advance a more sustainab

  • GlobeNewswire

    Green Hygienics Holdings Inc. (GRYN) Recruits Former Johnson & Johnson Head of Regulatory & Medical Affairs, Italy, as New Chief Scientific Officer

    SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Green Hygienics Holdings Inc. (OTCQB: GRYN) ("Green Hygienics" or the "Company") has appointed Dr. Francesca Serraino Fiory as the Company’s new Chief Scientific Officer. Dr. Serraino Fiory will oversee product development, accelerating the Company’s multibrand portfolio, and manage R&D efforts under the Company’s wholly owned biotechnology subsidiary, TruLife Biotech. She will also lead collaborative partnerships with research cen

Advertisement
Advertisement